Burtness BA - Search Results

1

NSD1- and NSD2-damaging mutations define a subset of laryngeal tumors with favorable prognosis.

Peri S, Izumchenko E, Schubert AD, Slifker MJ, Ruth K, Serebriiskii IG, Guo T, Burtness BA, Mehra R, Ross EA, Sidransky D, Golemis EA. Peri S, et al. Among authors: burtness ba. Nat Commun. 2017 Nov 24;8(1):1772. doi: 10.1038/s41467-017-01877-7. Nat Commun. 2017. PMID: 29176703 Free PMC article.

2

Antibody therapy for early-stage breast cancer: trastuzumab adjuvant and neoadjuvant trials.

Mehra R, Burtness B. Mehra R, et al. Expert Opin Biol Ther. 2006 Sep;6(9):951-62. doi: 10.1517/14712598.6.9.951. Expert Opin Biol Ther. 2006. PMID: 16918262 Review.

3

The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck.

Mehra R, Cohen RB, Burtness BA. Mehra R, et al. Among authors: burtness ba. Clin Adv Hematol Oncol. 2008 Oct;6(10):742-50. Clin Adv Hematol Oncol. 2008. PMID: 18997665 Free PMC article. Review.

4

Targeting EGFR resistance networks in head and neck cancer.

Ratushny V, Astsaturov I, Burtness BA, Golemis EA, Silverman JS. Ratushny V, et al. Among authors: burtness ba. Cell Signal. 2009 Aug;21(8):1255-68. doi: 10.1016/j.cellsig.2009.02.021. Epub 2009 Mar 1. Cell Signal. 2009. PMID: 19258037 Free PMC article. Review.

5

Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer.

Burtness B, Gibson M, Egleston B, Mehra R, Thomas L, Sipples R, Quintanilla M, Lacy J, Watkins S, Murren JR, Forastiere AA. Burtness B, et al. Ann Oncol. 2009 Jul;20(7):1242-8. doi: 10.1093/annonc/mdn787. Epub 2009 May 8. Ann Oncol. 2009. PMID: 19429872 Free PMC article. Clinical Trial.

6

Increased recurrences using intensity-modulated radiation therapy in the postoperative setting.

Turaka A, Li T, Sharma NK, Li L, Nicolaou N, Mehra R, Burtness B, Cohen RB, Lango MN, Horwitz EM, Ridge JA, Feigenberg SJ. Turaka A, et al. Am J Clin Oncol. 2010 Dec;33(6):599-603. doi: 10.1097/COC.0b013e3181c4c3cc. Am J Clin Oncol. 2010. PMID: 21063195

7

Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer.

Mehra R, Serebriiskii IG, Dunbrack RL Jr, Robinson MK, Burtness B, Golemis EA. Mehra R, et al. Drug Resist Updat. 2011 Dec;14(6):260-79. doi: 10.1016/j.drup.2011.08.002. Epub 2011 Sep 14. Drug Resist Updat. 2011. PMID: 21920801 Free PMC article. Review.

8

Nonsurgical management of oropharyngeal, laryngeal, and hypopharyngeal cancer: the Fox Chase Cancer Center experience.

Andrews G, Lango M, Cohen R, Feigenberg S, Burtness B, Mehra R, Ahmed S, Nicolaou N, Gaughan J, Ridge JA. Andrews G, et al. Head Neck. 2011 Oct;33(10):1433-40. doi: 10.1002/hed.21615. Epub 2010 Nov 10. Head Neck. 2011. PMID: 21928415

9

A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study.

Dotan E, Meropol NJ, Burtness B, Denlinger CS, Lee J, Mintzer D, Zhu F, Ruth K, Tuttle H, Sylvester J, Cohen SJ. Dotan E, et al. J Gastrointest Cancer. 2012 Dec;43(4):562-9. doi: 10.1007/s12029-012-9368-3. J Gastrointest Cancer. 2012. PMID: 22294255 Free PMC article. Clinical Trial.

10

Unilateral neck therapy in the human papillomavirus ERA: accepted regional spread patterns.

Galloway TJ, Lango MN, Burtness B, Mehra R, Ruth K, Ridge JA. Galloway TJ, et al. Head Neck. 2013 Feb;35(2):160-4. doi: 10.1002/hed.22929. Epub 2012 Feb 2. Head Neck. 2013. PMID: 22302641 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

262 results

Search Page

Filters